Value of claudin-4 immunostaining in the diagnosis of mesothelioma

American Journal of Clinical Pathology

Volumn 139, Issue 5, 2013, Pages 611-619

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Claudin 4; Immunohistochemistry; Mesothelioma

Indexed keywords

CLAUDIN 4;

ARTICLE; CARCINOMA; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

ADENOCARCINOMA; CLAUDIN-4; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; FEMALE; HUMANS; MALE; MELANOMA; MESOTHELIOMA; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; SARCOMA; SARCOMA, SYNOVIAL; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878054354     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP0B3YJBXWXJII     Document Type: Article

References (78)

1. Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch. 2007;451:669-680.
2. Soini Y, Kinnula V, Kahlos K, et al. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol. 2006;59:250-254.
3. González-Mariscal L, Betanzos A, Nava P, et al. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1-44.
4. Furuse M, Sasaki H, Fujimoto K, et al. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol. 1998;143:391-401.
5. Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A. 1999;96:511-516.
6. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-293.
7. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol. 2006;68:403-429.
8. Krause G, Winkler L, Mueller SL, et al. Structure and function of claudins. Biochim Biophys Acta. 2008;1778:631-645.
9. Lodi C, Szabo E, Holczbauer A, et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol. 2006;19:460-469.
10. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44:1-19.
11. Litvinov SV, Velders MP, Bakker HAM, et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994;125:437-446.
12. Winter MJ, Nagtegaal ID, van Krieken JHJM, et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139-2148.
13. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol. 1998;29:166-169.
14. Morgan RL, De Young BR, McGaughy VR, et al. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer. 1999;87:390-394.
15. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347.
16. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25:43-50.
17. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
18. Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13:347-352.
19. Porcell AI, De Young BR, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol. 2000;13:773-778.
20. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203-1214.
21. Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol. 2006;125:67-76.
22. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34-48.
23. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417-428.
24. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol. 1991;165:137-143.
25. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol. 1995;48:626-630.
26. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697-710.
27. Moch H, Oberholzer M, Dalquen P, et al. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue, part I: immunohistochemical findings. Virchows Arch A Pathol Anat Histopathol. 1993;423:19-27.
28. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
29. Ordóñez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol. 1998;109:85-89.
30. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529-536.
31. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55:662-668.
32. Ma CK, Zarbo RJ, Frierson HF Jr., et al. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol. 1993;99:551-557.
33. Rothacker D, Möbius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirtyyear autopsy study. Int J Gynecol Pathol. 1995;14:310-318.
34. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40:237-244.
35. Pritchard SA, Howat AJ, Edwards JM. Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma. Histopathology. 2003;43:197-199.
36. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol. 2001;20:155-159.
37. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology. 2004;45:452-459.
38. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409-1419.
39. Jordon D, Jagirdar J, Kaneko M. Blood group antigens Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol. 1989;135:931-937.
40. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol. 2000;31:980-987.
41. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
42. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies: evaluation of five epithelial markers. Virchows Arch. 1999;435:43-49.
43. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol. 1986;122:252-260.
44. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma: periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol. 1988;133:30-38.
45. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 1989;13:276-291.
46. Wick MR, Loy T, Mills SE, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol. 1990;21:759-766.
47. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer. 1991;67:655-662.
48. Brown RW, Clark GM, Tandon AK, et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993;24:347-354.
49. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
50. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol. 1997;21:1399-1408.
51. Nuti M, Teramoto YA, Mariani-Costantini R, et al. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-Associated antigen in human mammary carcinoma cell populations. Int J Cancer. 1982;29:539-545.
52. Galietta A, Pizzi C, Pettinato G, et al. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype. Oncol Rep. 2002;9:135-140.
53. Honma N, Takubo K, Arai T, et al. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS. 2006;114:712-719.
54. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29:381-389.
55. Nawgiri RS, Nagle JA, Wilbur DC, et al. Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium. Diagn Cytopathol. 2007;35:300-305.
56. Thor A, Gorstein F, Ohuchi N, et al. Tumor-Associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst. 1986;76:995-1006.
57. Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: a histochemical and immunohistochemical comparison. Am J Surg Pathol. 1989;13:659-670.
58. Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol. 1989;8:179-188.
59. Khoury N, Raju U, Crissman JD, et al. A comparative immunohistochemical study of peritoneal and ovarian serous tumors and mesotheliomas. Hum Pathol. 1990;21:811-819.
60. Ponnusamy MP, Venkatraman G, Singh AP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007;251:247-257.
61. Loy TS, Darkow GV, Quesenberry JT. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas: an immunohistochemical study with ultrastructural correlations. Am J Surg Pathol. 1995;19:173-182.
62. López-Ferrer A, Barranco C, de Bolós C. Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma. Am J Clin Pathol. 2002;118:749-755.
63. Gaffey MJ, Mills SE, Swanson PE, et al. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol. 1992;16:593-599.
64. González-Lois C, Ballestín C, Sotelo MT, et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology. 2001;38:528-534.
65. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol. 1992;141:827-833.
66. Pan CC, Chen PC, Chou TY, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003;34:1155-1162.
67. Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
68. Comin CE, Saieva C, Messerini L. h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139-1148.
69. Spagnolo DV, Whitaker D, Carrello S, et al. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Am J Clin Pathol. 1991;95:322-329.
70. Kadota A, Masutani M, Takei M, et al. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int J Oncol. 1999;15:1081-1089.
71. Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol. 2000;114:203-209.
72. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617.
73. Sim SJ, Ro JY, Ordóñez NG, et al. Metastatic renal cell carcinoma to the bladder: a clinicopathologic and immunohistochemical study. Mod Pathol. 1999;12:351-355.
74. Taki A, Nakatani Y, Misugi K, et al. Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases. Mod Pathol. 1999;12:310-317.
75. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma: a comparison between different commercially available antibodies. Cancer. 1994;73:464-469.
76. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol. 1989;2:8-12.
77. Adsay NV, Merati K, Nassar H, et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol. 2003;27:571-578.
78. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol. 2001;116:253-262.